Ioflupane I-123
Identification
- Name
- Ioflupane I-123
- Accession Number
- DB08824
- Description
Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Ioflupane I-123 (DB08824)
- Weight
- Average: 427.291
Monoisotopic: 427.076880092 - Chemical Formula
- C18H23FINO2
- Synonyms
- 123I-FP-CIT
- 123I-Ioflupane
- Iodine ioflupane (123I)
- Ioflupane ((123)I)
- Ioflupane (123I)
- Ioflupane I 123
- Ioflupane I(123)
- Ioflupano (123I)
- Ioflupanum (123I)
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Ioflupane I-123 is a SPECT (single photon emission computerized tomography) agent used to distinguish between Parkinson’s syndrome tremors and essential tremor.
- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
iodine-123 labeled ioflupanebinds selectively to striatal presynaptic dopamine neurons by binding reversibly to presynaptic dopamine transporters.
- Mechanism of action
Iodine-123 labeled ioflupane binds to presynaptic dopamine transporters. When Iodine-123 decays, a gammay ray is emmitted and detected through SPECT.
- Absorption
Absorption is 100% because administered I.V.
- Volume of distribution
Compared to the entire brain, about 30% of radioactivity is taken up by the striatum.
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
About 60% is excreted in the urine and 14% in the feces after 48 hours.
- Half-life
Half life is 13.2 hours.
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. Aclidinium Ioflupane I-123 may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Ioflupane I-123 may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Take with or without food.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Datscan Injection, solution 74 MBq/ml Intravenous Ge Healthcare B.V. 2016-09-08 Not applicable EU 
DaTscan Injection, solution 2 mCi/1mL Intravenous Medi-Physics Inc. dba GE Healthcare. 2011-03-01 Not applicable US 
Datscan Injection, solution 74 MBq/ml Intravenous Ge Healthcare B.V. 2016-09-08 Not applicable EU Striascan Injection, solution 74 MBq/mL Intravenous Cis Bio International 2020-12-16 Not applicable EU Striascan Injection, solution 74 MBq/mL Intravenous Cis Bio International 2020-12-16 Not applicable EU
Categories
- ATC Codes
- V09AB03 — Iodine ioflupane (123i)
- Drug Categories
- Alkaloids
- Aza Compounds
- Azabicyclo Compounds
- Carbon Radioisotopes
- Central Nervous System
- Diagnostic Radiopharmaceuticals
- Diagnostic Uses of Chemicals
- Drugs that are Mainly Renally Excreted
- Fluorine Radioisotopes
- Iodine (123I) Compounds
- Iodine Radioisotopes
- Radioactive Diagnostic Agent
- Radiopharmaceutical Activity
- Tropanes
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenyltropanes. These are compounds containing a phenyl group linked to a tropane moiety. Tropane is an organonitrogenous [3.2.1] bicyclic organic compound.
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- Tropane alkaloids
- Sub Class
- Phenyltropanes
- Direct Parent
- Phenyltropanes
- Alternative Parents
- Phenylpiperidines / Piperidinecarboxylic acids / Aralkylamines / Iodobenzenes / Aryl iodides / N-alkylpyrrolidines / Methyl esters / Trialkylamines / Amino acids and derivatives / Azacyclic compounds show 8 more
- Substituents
- Alkyl fluoride / Alkyl halide / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Aryl halide / Aryl iodide / Azacycle / Benzenoid show 27 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- organofluorine compound, azabicycloalkane, methyl ester (CHEBI:68855)
Chemical Identifiers
- UNII
- 3MM99T8R5Q
- CAS number
- 155798-07-5
- InChI Key
- HXWLAJVUJSVENX-HFIFKADTSA-N
- InChI
- InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4
- IUPAC Name
- methyl (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-[4-(¹²³I)iodophenyl]-8-azabicyclo[3.2.1]octane-2-carboxylate
- SMILES
- [H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C([123I])C=C1)C(=O)OC)N2CCCF
References
- General References
- Tolosa E, Borght TV, Moreno E: Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007 Dec;22(16):2346-51. [PubMed:17914722]
- Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V: Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000 May;15(3):503-10. [PubMed:10830416]
- Link [Link]
- External Links
- KEGG Drug
- D10014
- PubChem Compound
- 3086674
- PubChem Substance
- 175427106
- ChemSpider
- 2343241
- 1426874
- ChEBI
- 68855
- ChEMBL
- CHEMBL3989517
- ZINC
- ZINC000100091991
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Ioflupane_(123I)
- FDA label
- Download (655 KB)
- MSDS
- Download (97.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Enrolling by Invitation Diagnostic Dementia / Mild Cognitive Impairment (MCI) / Parkinsonism / REM Sleep Behavior Disorder 1 3 Completed Diagnostic Alzheimer's / Dementia, Vascular / Diffuse Lewy Body Disease / Non-DLB Dementia 1 3 Completed Diagnostic Amyotrophic Lateral Sclerosis (ALS) 1 3 Recruiting Diagnostic Multiple System Atrophy (MSA) / Parkinson's Disease (PD) / Parkinsonian Syndromes / Progressive Supranuclear Palsy (PSP) 1 3 Withdrawn Diagnostic Parkinson's Disease (PD) 1 2 Active Not Recruiting Other Parkinson's Disease (PD) 1 2 Completed Basic Science Pain / Parkinson's Disease (PD) 1 2 Terminated Diagnostic Clear Cell Renal Cell Carcinoma 1 1 Not Yet Recruiting Diagnostic Healthy Subjects (HS) 1 0 Completed Other Alzheimer's Disease (AD) / Healthy Volunteers / Progressive Supranuclear Palsy (PSP) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution 74 MBQ/ML Injection, solution Intravenous 2 mCi/1mL Injection, solution Intravenous 74 MBq/ml Injection 74 MBq/mL Injection, solution Parenteral 74 MBq/ml - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5310912 No 1994-05-10 2013-02-25 US
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 82-83 Not Available water solubility Soluble in water Not Available - Predicted Properties
Property Value Source Water Solubility 0.00566 mg/mL ALOGPS logP 4.24 ALOGPS logP 3.7 ChemAxon logS -4.9 ALOGPS pKa (Strongest Basic) 9.46 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 29.54 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 97.34 m3·mol-1 ChemAxon Polarizability 38.75 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9761 Blood Brain Barrier + 0.9729 Caco-2 permeable + 0.5307 P-glycoprotein substrate Non-substrate 0.5154 P-glycoprotein inhibitor I Inhibitor 0.7921 P-glycoprotein inhibitor II Inhibitor 0.6468 Renal organic cation transporter Inhibitor 0.7311 CYP450 2C9 substrate Non-substrate 0.7871 CYP450 2D6 substrate Non-substrate 0.6487 CYP450 3A4 substrate Substrate 0.5905 CYP450 1A2 substrate Inhibitor 0.5832 CYP450 2C9 inhibitor Non-inhibitor 0.6451 CYP450 2D6 inhibitor Non-inhibitor 0.5706 CYP450 2C19 inhibitor Non-inhibitor 0.5324 CYP450 3A4 inhibitor Non-inhibitor 0.8127 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5778 Ames test Non AMES toxic 0.7173 Carcinogenicity Non-carcinogens 0.927 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.8764 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7236 hERG inhibition (predictor II) Inhibitor 0.6662
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Monoamine transmembrane transporter activity
- Specific Function
- Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A3
- Uniprot ID
- Q01959
- Uniprot Name
- Sodium-dependent dopamine transporter
- Molecular Weight
- 68494.255 Da
References
- Link [Link]
Drug created on December 27, 2012 21:00 / Updated on June 12, 2020 17:42